Bridging the Gap between Statistical and Biological Epistasis in Alzheimer's Disease

Alzheimer's disease affects millions of people worldwide and incidence is expected to rise as the population ages, but no effective therapies exist despite decades of research and more than 20 known disease markers. Research has shown that Alzheimer's disease's missing heritability remains extensive with an estimated 25% of phenotypic variance unexplained by known variants. The missing heritability may be explained by missing variants or by epistasis. Researchers often focus on individual loci rather than epistatic interactions, which is likely an oversimplification of the underlying biology since most phenotypes are affected by multiple genes. Focusing research efforts on epistasis will be critical to resolving Alzheimer's disease etiology, and a major key to identifying and properly interpreting key epistatic interactions will be bridging the gap between statistical and biological epistasis. This review covers the current state of epistasis research in Alzheimer's disease and how researchers can bridge the gap between statistical and biological epistasis to help resolve Alzheimer's disease etiology.

[1]  A. Singleton,et al.  TREM2 variants in Alzheimer's disease. , 2013, The New England journal of medicine.

[2]  A. Smith,et al.  Synergy between the C2 allele of transferrin and the C282Y allele of the haemochromatosis gene (HFE) as risk factors for developing Alzheimer’s disease , 2004, Journal of Medical Genetics.

[3]  G. Perry,et al.  Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[4]  D. Allison,et al.  Detection of gene x gene interactions in genome-wide association studies of human population data. , 2007, Human heredity.

[5]  Benjamin F. J. Verhaaren,et al.  Alzheimer's Disease Genes and Cognition in the Nondemented General Population , 2013, Biological Psychiatry.

[6]  Jason H. Moore,et al.  Renin-angiotensin system gene polymorphisms and coronary artery disease in a large angiographic cohort: detection of high order gene-gene interaction. , 2007, Atherosclerosis.

[7]  D. G. Clark,et al.  Common variants at MS 4 A 4 / MS 4 A 6 E , CD 2 AP , CD 33 and EPHA 1 are associated with late-onset Alzheimer ’ s disease , 2011 .

[8]  J. Gu,et al.  High-order interactions among genetic polymorphisms in nucleotide excision repair pathway genes and smoking in modulating bladder cancer risk. , 2007, Carcinogenesis.

[9]  O. Combarros,et al.  Interaction between HMGCR and ABCA1 cholesterol-related genes modulates Alzheimer's disease risk , 2009, Brain Research.

[10]  A. Weverling-Rijnsburger,et al.  Patients with Alzheimer's disease display a pro-inflammatory phenotype , 2001, Experimental Gerontology.

[11]  J. Haines,et al.  Genome-Wide Association Study of Late-Onset Alzheimer Disease Identifies Disease-Associated Variants in MS4A4/MS4A6E, CD2AP, CD33, and EPHA1 , 2011, Alzheimer's & Dementia.

[12]  J. Connor,et al.  A histochemical study of iron, transferrin, and ferritin in Alzheimer's diseased brains , 1992, Journal of neuroscience research.

[13]  G. Wong,et al.  Gene-gene interactions for asthma and plasma total IgE concentration in Chinese children. , 2006, The Journal of allergy and clinical immunology.

[14]  H He,et al.  Pair-Wise Multifactor Dimensionality Reduction Method to Detect Gene-Gene Interactions in A Case-Control Study , 2009, Human Heredity.

[15]  M. Owen,et al.  Suggestive synergy between genetic variants in TF and HFE as risk factors for Alzheimer's disease , 2009, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[16]  Susan E Hodge,et al.  Non-replication of association studies: “pseudo-failures” to replicate? , 2007, Genetics in Medicine.

[17]  A. Singleton,et al.  TREM2 Variants in Alz hei mer's Disease , 2012 .

[18]  R. Loewith,et al.  Plasma membrane stress induces relocalization of Slm proteins and activation of TORC2 to promote sphingolipid synthesis , 2012, Nature Cell Biology.

[19]  Qiang Yang,et al.  BOOST: A fast approach to detecting gene-gene interactions in genome-wide case-control studies , 2010, American journal of human genetics.

[20]  R. Elston,et al.  Identification of gene‐gene interactions in the presence of missing data using the multifactor dimensionality reduction method , 2009, Genetic epidemiology.

[21]  N. Craddock,et al.  Polymorphism in AACT gene may lower age of onset of Alzheimer's disease , 1996, Neuroreport.

[22]  Nick C Fox,et al.  Common variants in ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer’s disease , 2011, Nature Genetics.

[23]  David B Allison,et al.  "Are we there yet?": Deciding when one has demonstrated specific genetic causation in complex diseases and quantitative traits. , 2003, American journal of human genetics.

[24]  H. Drexel,et al.  Synergistic effects of the apolipoprotein E epsilon3/epsilon2/epsilon4, the cholesteryl ester transfer protein TaqIB, and the apolipoprotein C3 -482 C>T polymorphisms on their association with coronary artery disease. , 2008, Atherosclerosis.

[25]  Mario Cortina-Borja,et al.  Open Access Journal of Neuroinflammation Replication by the Epistasis Project of the Interaction between the Genes for Il-6 and Il-10 in the Risk of Alzheimer's Disease , 2022 .

[26]  P. Crane,et al.  Alzheimer’s Disease: Analyzing the Missing Heritability , 2013, PloS one.

[27]  H. Soininen,et al.  Butyrylcholinesterase K variant and apolipoprotein E4 genes do not act in synergy in Finnish late-onset Alzheimer's disease patients , 1998, Neuroscience Letters.

[28]  D. G. Clark,et al.  Common variants in MS4A4/MS4A6E, CD2uAP, CD33, and EPHA1 are associated with late-onset Alzheimer’s disease , 2011, Nature Genetics.

[29]  Scott M. Williams,et al.  A balanced accuracy function for epistasis modeling in imbalanced datasets using multifactor dimensionality reduction , 2007, Genetic epidemiology.

[30]  Erick R. Scott,et al.  Rare coding variants in the phospholipase D3 gene confer risk for Alzheimer’s disease , 2013, Nature.

[31]  Jongjoo Kim,et al.  Multifactor dimensionality reduction (MDR) analysis to detect single nucleotide polymorphisms associated with a carcass trait in a Hanwoo population , 2008 .

[32]  D. M. Penny,et al.  The hemochromatosis gene product complexes with the transferrin receptor and lowers its affinity for ligand binding. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[33]  A. Townsend,et al.  Role of HFE in iron metabolism, hereditary haemochromatosis, anaemia of chronic disease, and secondary iron overload , 2002, The Lancet.

[34]  Jason H. Moore,et al.  Power of multifactor dimensionality reduction for detecting gene‐gene interactions in the presence of genotyping error, missing data, phenocopy, and genetic heterogeneity , 2003, Genetic epidemiology.

[35]  J. Connor,et al.  Transferrin and Iron in Normal, Alzheimer's Disease, and Parkinson's Disease Brain Regions , 1995, Journal of neurochemistry.

[36]  Mario Cortina-Borja,et al.  Discovery by the Epistasis Project of an epistatic interaction between the GSTM3 gene and the HHEX/IDE/KIF11 locus in the risk of Alzheimer's disease , 2013, Neurobiology of Aging.

[37]  Michael J. Wade,et al.  Epistasis, complex traits, and mapping genes , 2004, Genetica.

[38]  Peter Bock,et al.  Using a hierarchical approach to avoid over-fitting in early vision , 1994, Proceedings of 12th International Conference on Pattern Recognition.

[39]  Kristel Van Steen,et al.  Genome-wide association interaction analysis for Alzheimer's disease , 2014, Neurobiology of Aging.

[40]  N E Day,et al.  Multi-factor dimensionality reduction applied to a large prospective investigation on gene-gene and gene-environment interactions. , 2006, Carcinogenesis.

[41]  M. L. Calle,et al.  Model‐Based Multifactor Dimensionality Reduction for detecting epistasis in case–control data in the presence of noise , 2011, Annals of human genetics.

[42]  O. Combarros,et al.  Gene–gene interaction between interleukin-6 and interleukin-10 reduces AD risk , 2004, Neurology.

[43]  J. H. Moore,et al.  Multifactor-dimensionality reduction reveals high-order interactions among estrogen-metabolism genes in sporadic breast cancer. , 2001, American journal of human genetics.

[44]  E. Corder,et al.  Transferrin neutralization of amyloid beta 25-35 cytotoxicity. , 2004, Clinica chimica acta; international journal of clinical chemistry.

[45]  Ole A. Andreassen,et al.  A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline , 2012, Nature.

[46]  Jason H. Moore,et al.  An application of conditional logistic regression and multifactor dimensionality reduction for detecting gene-gene Interactions on risk of myocardial infarction: The importance of model validation , 2004, BMC Bioinformatics.

[47]  M. Hart,et al.  Over‐expression of heat shock factor 1 phenocopies the effect of chronic inhibition of TOR by rapamycin and is sufficient to ameliorate Alzheimer's‐like deficits in mice modeling the disease , 2013, Journal of neurochemistry.

[48]  Taesung Park,et al.  Log-linear model-based multifactor dimensionality reduction method to detect gene-gene interactions , 2007, Bioinform..

[49]  A. Ritchie,et al.  A new promoter polymorphism in the alpha-1-antichymotrypsin gene is a disease modifier of Alzheimer’s disease , 2005, Neurobiology of Aging.

[50]  Yijun Zuo,et al.  An entropy-based approach for testing genetic epistasis underlying complex diseases. , 2008, Journal of theoretical biology.

[51]  A. Hofman,et al.  Variant of TREM2 associated with the risk of Alzheimer's disease. , 2013, The New England journal of medicine.

[52]  Todd Holden,et al.  A flexible computational framework for detecting, characterizing, and interpreting statistical patterns of epistasis in genetic studies of human disease susceptibility. , 2006, Journal of theoretical biology.

[53]  E. Corder,et al.  Transferrin neutralization of amyloid β 25-35 cytotoxicity , 2004 .

[54]  M. Ritchie,et al.  Exploring the Performance of Multifactor Dimensionality Reduction in Large Scale SNP Studies and in the Presence of Genetic Heterogeneity among Epistatic Disease Models , 2008, Human Heredity.

[55]  R. Stewart,et al.  Assessment of association between mitochondrial aldehyde dehydrogenase polymorphism and Alzheimer’s disease in an older Korean population , 2004, Neurobiology of Aging.

[56]  Mee Young Park,et al.  Penalized logistic regression for detecting gene interactions. , 2008, Biostatistics.

[57]  J. H. Moore,et al.  Multifactor-dimensionality reduction shows a two-locus interaction associated with Type 2 diabetes mellitus , 2004, Diabetologia.

[58]  Mark T. W. Ebbert,et al.  Genetics of Alzheimer's Disease , 2013, BioMed research international.

[59]  L. Polito,et al.  The SIRT2 polymorphism rs10410544 and risk of Alzheimer’s disease in two Caucasian case–control cohorts , 2013, Alzheimer's & Dementia.

[60]  Scott M. Williams,et al.  Traversing the conceptual divide between biological and statistical epistasis: systems biology and a more modern synthesis. , 2005, BioEssays : news and reviews in molecular, cellular and developmental biology.

[61]  Jason H. Moore,et al.  Multifactor dimensionality reduction software for detecting gene-gene and gene-environment interactions , 2003, Bioinform..

[62]  Mario Cortina-Borja,et al.  Epistasis in sporadic Alzheimer's disease , 2009, Neurobiology of Aging.

[63]  Margaret R Karagas,et al.  Concordance of multiple analytical approaches demonstrates a complex relationship between DNA repair gene SNPs, smoking and bladder cancer susceptibility. , 2006, Carcinogenesis.

[64]  J. Haines,et al.  Drug transporter and metabolizing enzyme gene variants and nonnucleoside reverse-transcriptase inhibitor hepatotoxicity. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[65]  Sara Marsal,et al.  Identification of a two-loci epistatic interaction associated with susceptibility to rheumatoid arthritis through reverse engineering and multifactor dimensionality reduction. , 2007, Genomics.

[66]  Perry G. Ridge,et al.  Population-based Analysis of Alzheimer’s Disease Risk Alleles Implicates Genetic Interactions , 2014, Biological Psychiatry.

[67]  M. Imagawa,et al.  Deficiency in mitochondrial aldehyde dehydrogenase increases the risk for late-onset Alzheimer's disease in the Japanese population. , 2000, Biochemical and biophysical research communications.

[68]  Jason H Moore,et al.  Computational analysis of gene-gene interactions using multifactor dimensionality reduction , 2004, Expert review of molecular diagnostics.

[69]  A. Smith,et al.  Using meta-analysis to explain the diversity of results in genetic studies of late-onset Alzheimer’s disease and to identify high-risk subgroups , 2001, Neuroscience.

[70]  O. Combarros,et al.  Interaction of the H63D Mutation in the Hemochromatosis Gene with the Apolipoprotein E Epsilon 4 Allele Modulates Age at Onset of Alzheimer’s Disease , 2003, Dementia and Geriatric Cognitive Disorders.

[71]  Nick C Fox,et al.  Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease , 2013, Nature Genetics.

[72]  E. Shin,et al.  Multilocus analysis of atopy in Korean children using multifactor-dimensionality reduction , 2006, Thorax.

[73]  Laurent Briollais,et al.  Methodological issues in detecting gene-gene interactions in breast cancer susceptibility: a population-based study in Ontario , 2007, BMC medicine.